UK markets close in 6 hours 41 minutes
  • FTSE 100

    7,933.67
    +48.50 (+0.62%)
     
  • FTSE 250

    20,286.68
    -17.13 (-0.08%)
     
  • AIM

    881.11
    -2.12 (-0.24%)
     
  • GBP/EUR

    1.1276
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2128
    +0.0058 (+0.48%)
     
  • BTC-GBP

    18,721.02
    -491.91 (-2.56%)
     
  • CMC Crypto 200

    523.11
    -13.78 (-2.57%)
     
  • S&P 500

    4,117.86
    -46.14 (-1.11%)
     
  • DOW

    33,949.01
    -207.68 (-0.61%)
     
  • CRUDE OIL

    78.41
    -0.06 (-0.08%)
     
  • GOLD FUTURES

    1,893.40
    +2.70 (+0.14%)
     
  • NIKKEI 225

    27,584.35
    -22.11 (-0.08%)
     
  • HANG SENG

    21,624.36
    +340.84 (+1.60%)
     
  • DAX

    15,576.17
    +164.12 (+1.06%)
     
  • CAC 40

    7,197.71
    +77.88 (+1.09%)
     

DEINOVE - Update on the receivership proceedings

Deinove
Deinove

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court met on January 13, 2023 to examine the case and reserved its decision until January 23, 2023.

The listing of the Company's shares (ISIN: FR0010879056), which has been suspended since January 11, 2023, will remain suspended.

ABOUT DEINOVE

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.

The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

This breakthrough approach gave rise to one of the world’s first specialized micro-biotechnology platforms and a unique collection of nearly 10,000 rare strains and thousands of bacterial extracts. Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection, one of the world’s first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.

Located at the heart of the Euromedecine park in Montpellier, DEINOVE has been listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic, technological, industrial and institutional partners.

CONTACTS

Investors

Mario Alcaraz

Chief Financial and Administrative Officer

+33 (0)4 48 19 01 00

ir@deinove.com

Media

ATCG Partners

+33 (0)9 81 87 46 72

communication@deinove.com

 

Attachment